1. Participants
The participants were included in the psychiatric departments of three European hospital centers: the Creteil University Hospital, France (Center-1), the Grenoble University Hospital, France (Center-2), and the Geneva University Hospital, Switzerland (Center-3). Clinical diagnosis was established by specialized psychiatrists using the DSM-IV-TR criteria and confirmed by the Mini-International Neuropsychiatric Interview (MINI) for the Geneva center or the Structured Clinical Interview (SCID) for the two centers in France, both administered by a trained clinician. Each patient sample was matched on sex and age with healthy controls (HC) from its respective center (Table 1). Control subjects were selected and included in the study after an interview with a psychiatrist, according to the SCID, to exclude any psychiatric disorder.
Table 1
Demographic and clinical characteristics of the samples
| Bipolar disorder (N = 127) | Healthy controls (N = 131) |
| N | mean/freq | SD | N | mean/freq | SD |
Age | 127 | 35.6 | 11.6 | 131 | 34.2 | 11.4 |
Sex (% males) | 127 | 54.3% | | 131 | 48.9% | |
Handedness (% right-handedness) | 86 | 84.9% | | 83 | 81.9% | |
Age of onset | 94 | 22.9 | 8.0 | | | |
Illness duration | 93 | 13.4 | 9.6 | | | |
BD Type Type 1 Type 2 | | 94 65 28 | | | | |
Depression Score (MADRS) | 103 | 6.3 | 6.9 | 30 | 1.1 | 1.7 |
Mania Score (YMRS) | 101 | 2.4 | 3.6 | 30 | 0.4 | 1.0 |
Number of depressive episodes | 63 | 5.0 | 7.9 | | | |
Number of manic episodes | 64 | 3.3 | 3.8 | | | |
On medication Antipsychotics Antidepressants Anticonvulsivants Lithium | 101 | 93.9% 46% 21.7% 44.6% 50.5% | 24.1% 50.1% 41.5% 50.0% 50.3% | | | |
N = number of available data |
The exclusion criteria for all participants consisted of: (i) age outside the range of 18–65; (ii) history of alcohol or drug abuse; (iii) any current or past neurological/medical diseases affecting cognition; (iv) any history of head trauma with loss of consciousness; (v) contraindication for MRI.
For BD patients, additional exclusion criteria were: (i) any current other Axis I psychiatric disorder; (ii) history of electroconvulsive therapy during the previous year.
For HC, additional exclusion criteria included: (i) history of psychiatric illness; (ii) family history of major psychiatric or neurological illness; (iii) medical treatment affecting cerebral activity. All participants were also screened for MRI safety.
In total, 128 BD patients (Center-1: 66, Center-2: 17, Center-3: 45) and 133 HC were included in the study (Center-1: 82, Center-2: 16, Center-3: 35).
The study protocol was approved by the institutional Ethics Committee of each center (i.e., the local University Hospital Ethics Committees in France and the Cantonal Commission on Ethics in Human Research of Geneva) and written informed consent was obtained from all the participants.
<Insert here Table 1>
2. Clinical assessment
Before MRI scanning, the severity of manic symptoms was evaluated by the Young Mania Rating Scale (YMRS) (30) and the severity of depressive symptoms by the Montgomery-Asberg Depression Rating Scale (MADRS) (31).
A higher YMRS score indicates more severe manic symptoms, and we used a cut-off score ≥ 4 to define mania or residual symptoms of mania (manic BD) (32). Similarly, a higher MADRS score indicates more severe depression, and we used a cut-off score ≥ 7 to define a depressive state (depressed BD) (33)(34). MADRS and YMRS scores were available for 103 and 101 patients with BD, respectively.
3. MRI data acquisition
All participants were instructed to simply rest, let their thoughts wander or not to think about anything specific, and not to fall asleep. A rs-fMRI sequence as well as an anatomical T1-weighted MRI sequence were acquired for each subject and each site with the following parameters:
3.1. Center 1 (Paris)
MRI data were collected at the Neurospin neuroimaging platform (Commissariat à l’Energie Atomique, Saclay, France) using two 3T Siemens MR scanners:
-
Magnetom TrioTim syngo MR B17, with 12-channel head coils respectively. Functional images were acquired through an echo-planar imaging sequence with the following parameters: TR = 2000 ms, TE = 27 ms, slices = 35, matrix size = 64 x 64 pixels, FA = 81°, FOV = 192 x 192 mm2, voxel size = 3 x 3 x 3 mm3, interslice gap = 3 mm, and total 360 volumes with a scan time of 12 minutes. A high-resolution T1-weighted anatomical scan was also acquired (MPRAGE; TR/TI/TE = 2300/900/2.98 ms; FA = 9°; voxel dimensions = 1.0 mm isotropic; 256 x 256 x 192 voxels).
-
Magnetom Prisma, with 64-channel head coils. Functional images were acquired through an echo-planar imaging sequence with the following parameters: TR = 1430 ms, TE = 20 ms, slices = 62, matrix size = 76 x 76 pixels, FA = 68°, voxel size = 2 x 2 x 2.5 mm3, interslice gap = 2.5 mm, multiband acceleration factor = 2. A high-resolution T1-weighted anatomical scan was also acquired (MPRAGE; TR/TI/TE = 2300/900/2.98 ms; FA = 9°; voxel dimensions = 1.0 mm isotropic; 240 x 256 x 160 voxels).
3.2. Center 2 (Grenoble)
Imaging data were acquired using a whole-body 3T MR scanner (BrukerMedSpecS300- Grenoble MRI facility IRMaGE) with a fMRI acquisition sequence. Functional images were collected through an echo-planar imaging sequence with the following parameters: TR = 2500 ms, TE = 30 ms, slices = 37, matrix size = 72 x 72 pixels, FA = 77°, FOV = 216 x 216 mm2, voxel size = 3 x 3 x 3.5 mm3, and total 144 volumes with a scan time of 6 minutes. Finally, a T1-weighted height-resolution three-dimensional anatomical volume was acquired (0.8 mm in plane resolution, 0.8 mm thickness; FOV = 224x256x176; acquisition matrix = 280x320x220 pixels).
3.3. Center 3 (Geneva)
MRI data were obtained from two prospective cohorts, acquired at the University of Geneva on a 3T Siemens Magnetom TrioTim scanner with a 32-channel head coil:
-
For the first cohort, functional images were collected through an echo-planar imaging sequence with the following parameters: TR = 2100 ms, TE = 30 ms, slices = 36, matrix size = 64x64 pixels, FA = 80°, voxel size = 3.2 x 3.2 x 3.2 mm3, interslice gap = 3.84 mm, and total 250 volumes with a scan time of 8 minutes 45 seconds. A high-resolution whole brain anatomical scan was acquired with a T1-weighted 3D sequence (MPRAGE; TR/TI/TE = 1900/900/2.27 ms; FA = 9°; voxel dimensions = 1.0 mm isotropic; 256 x 256 x 192 voxels).
-
For the second cohort, whole brain functional images were collected using a BOLD-weighted EPI sequence with the following parameters: TR = 2100 ms, TE = 30 ms, slices = 36, FA = 90°; FOV = 205 mm; matrix size = 64 x 64 pixels, voxel size = 3.2 x 3.2 x 3.2 mm3. 250 volumes were acquired for a total duration of 8 minutes 45 seconds. A T1-weighted volume for anatomical reference was collected with high-resolution three-dimensional T1-weighted MPRAGE sequence (TR/TI/TE = 1900/900/2.32 ms; flip angle = 9°; voxel dimensions = 0.9 mm isotropic; FOV = 230 mm).
4. MRI data processing
We discarded the 5 first frames of functional data, after which the preprocessing of rs-fMRI data was conducted using fMRIPrep (35). Concisely, this standardized pipeline included the following steps: slice-timing correction, motion correction, skull stripping, and estimation of motion parameters and other nuisance signal time series. To remove head motion effects, a Friston 24-parameter model (36) was used to regress out head motion effects from the realigned data (i.e., 6 head motion parameters, 6 head motion parameters one time point before, and the 12 corresponding squared parameters). The physiological noise (cerebrospinal fluid and white matter signals) was also regressed as nuisance covariates. Given the ongoing debates about optimal preprocessing steps in the resting-state functional MRI community (37) (38) and knowing that the global mean signal contains measurable effects of certain pathologies, we decided not to correct for its effect (39). After nuisance covariate regression, the resultant data were linearly detrended and filtered at a range between 0.01 Hz and 0.08 Hz to select low frequency signals. All functional data were spatially normalized to the Montreal Neurological Institute EPI template (MNI 152).
Exclusion criteria after pre-processing for all subjects were: (i) visual artifacts in the medial temporal lobe (n = 1), (ii) signal-to-noise ratio and temporal signal-to-noise ratio less than − 2.5 SD of their cohort (n = 2). We therefore included 127 BD patients and 131 HC in the final analysis.
For each subject, we also excluded volumes with a mean framewise displacement (FD) > 0.5 mm or a mean BOLD data variance from the prior volume (DVARS) > 50% along with the previous and the following volume (40)(41)(42). This represented 0.3% of the total volumes acquired.
5. Functional connectivity analysis
ROI-to-ROI analyses were performed using the AMY, the NAc and the HIP subregions as seeds. Each unilateral subcortical nucleus was divided into two independent areas based on the recently developed functional MRI Atlas of Tian (43). Consequently, for each hemisphere, the AMY was divided into lateral (lAMY) and medial (mAMY) amygdala, the HIP into anterior (aHIP) and posterior (pHIP) hippocampus and the NAc into shell (NAc-shell) and core (NAc-core) subparts. These seed regions were created in the MNI standard space using Nilearn Python library (Fig. 1). The signal time course was extracted from the 12 resulting ROIs (6 by hemisphere) in both patients and controls and the mean signal time course was calculated for each seed region and each subject. Afterwards, we computed temporal correlations between the BOLD signals of four seed of interest (ROIs): right lAMY (MNI coordinates: 28, -2, -22), right mAMY (MNI : 22, -6, -16), left lAMY (MNI : -26, -2, -22), left mAMY (MNI : -20, -6, -16), and eight target ROIs: right aHIP (MNI : 26, -14, -20), right pHIP (MNI : 28, -32, -8), left aHIP (MNI : -24, -14, -20), left pHIP (MNI : -26, -32, -8), right NAc-shell (MNI : 12, 10, -6), right NAc-core (MNI : 14, 18, -2), left NAc-shell (MNI : -10, 10, -6), left NAc-core (MNI : -12, 18, -2). Each ROI was visually inspected for each subject to assure a precise localization within anatomical boundaries.
<Insert here Fig. 1>
6. Statistical analysis
6.1. Whole-sample analyses
At the individual subject level, correlations were obtained by extracting the mean BOLD time course from each amygdala subregion i seed (mAMY and lAMY, right and left) and then calculating Pearson’s product moment correlation between that time course and the time course of other regions j of interest (i.e., NAc-shell, NAc-core, pHIP and aHIP, right and left). This matrix of correlation coefficients was then converted to normally distributed Z-scores using Fisher’s r-to-z transformation to allow for second-level analysis. All subsequent statistical analyses were conducted on these transformed data.
FC scores (Z-scores) for each subject were entered into a second-level random-effects analyses to quantitatively compare the amygdala subregions’ FC between the groups (BD vs. HC). We used linear mixed models including the diagnosis as fixed factor (BD vs. HC) as well as Age and Sex as covariates and Site as random effect (R version 4.1.2, lme4 package, Bates et al., 2022) (44). For each pair of ROIs, we fitted the following model:
FC (ROIi-ROIj) = β0 (Intercept) + β1 * Diagnosis + β2 * Age + β3 * Sex + random effect (Site)
We used Benjamini-Hochberg correction to control for multiple comparisons.
6.2. Sub-sample analyses
6.2.1. Correlations with psychiatric symptoms
To evaluate the correlation between the intensity of the mood symptoms and FC in BD patients, FC values (Z-scores) from each pair of ROIs (n = 12) were correlated with the MADRS and the YMRS scores using a non-parametric Pearson’s correlation test (with a significance level threshold of p < 0.05 after FDR correction).
6.2.2. Subgroups analyses
Then, given our initial hypothesis, we confined our analysis and specifically compared AMY/HIP connectivity between depressed (n = 31) and non-depressed (n = 72) BD patients / HC (n = 131) and AMY/NAc connectivity between manic (n = 29) and non-manic (n = 74) BD patients / HC (n = 131). For that purpose, we also used linear mixed models with the subgroup as fixed factor and the Age and Gender as covariates, and Site as random effect, as follows:
FC (ROIi-ROIj) = β0 (Intercept) + β1 * Subgroup + β2 * Age + β3 * Sex + random effect (Site)